首页> 中文期刊> 《世界核心医学期刊文摘:心脏病学分册》 >二尖瓣人工瓣膜合并心房扩大患者接受经导管射频消融术治疗房颤的安全性、可行性及有效性

二尖瓣人工瓣膜合并心房扩大患者接受经导管射频消融术治疗房颤的安全性、可行性及有效性

         

摘要

OBJECTIVES: Few data have been published on transcatheter ablation of atrial fibrillation(AF) in patients with mitral valve prostheses. Thus, we sought to report our experience. BACKGROUND: Ablation is an effective treatment for AF. Patients with prosthetic mitral valves represent a special group because of an increased risk from the ablation procedure due to the possibility of damage to the prosthetic valve. METHODS: Between July 2001 and July 2003, 26 patients with mitral valve prostheses(MVP) underwent circumferential pulmonary vein ablation for AF. A matched group of 52 ablated patients without MVP acted as control subjects. After a blanking period of three months, a follow-up of 12 months was considered for MVP patients and controls. Holter recordings were performed in all subjects at 3, 6, and 12 months. RESULTS: Radiation exposure was higher in the MVP group, with fluoroscopy times of 35.3±21 min versus 20.9±15 min in controls. At the end of follow-up, 73%of MVP patients were in sinus rhythm, compared with 75%of controls. Atrial tachycardia occurred in six(23%) MVP patients, requiring repeat ablation in three, and one(2%) control subject, which settled without treatment. One transient ischemic attack and one femoral pseudoaneurysm occurred in the MVP group. No complications occurred in the control group. CONCLUSIONS: Ablation of AF in patients with MVP is feasible, with outcomes similar to those of standard patients. Complications were higher among MVP patients with a greater radiation exposure and a higher incidence of postablation atrial tachycardia.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号